신증후출혈열 환자에서 경구 Ribavirin 의 투여 효과 = The Efficacy of Oral Ribavirin Therapy in Hemorrhagic Fever with Renal Syndrome

다국어 초록 (Multilingual Abstract)

N/A

다국어 초록 (Multilingual Abstract)

(ribavirin group). The control group was 17 patients (15 in 1992, 2 in 1993) and the ribavirin group was 15 patients(all in 1993). No difference was noted between ribavirin and control group at baseline. Results: 1) There were no baseline prognostic factors for mortality in control group. No significant difference in mortality was seen between ribavirin and control group(0/15 vs. 2/17). 2) There were no baseline prognostic factors for hemorrhage in control group. Hemorrhagic complications were significantly decreased in ribavirin group (1/15 vs 7/17, p<0.05)and the ribavirin treatment correlated inversely with the development of hemorrhage(odds ratio 0.16, 95% confidence interval 0.02 to 1.19,p=0.02). By stepwise multiple logistc regression, the variable which better contributed to explain the development of hemorrhagic complications in our patients were ribavirin treatment. 3) No significant differences in duration of febrile, hypotensive and oliguric stage, and skipping of hypotensive and oliguric stage between two groups were seen. But duration of diuretic stage was significantly decreased in ribavirin group(4.7±4.2 vs. 11.4±7.6 days, p<0.05). 4) Mild anemia was observed in most patients and no difference in hematocrit was observed between two groups. Conclusion: Oral ribavirin therapy was effective in the reduction of hemorrhagic complications and duration of diuretic stage. But prospective, double-blind and placebo-controlled study with larger number of patients would be nececsary.